论文部分内容阅读
目的 :将堕胎药物米非司酮载入固体脂质纳米粒 (SLNs)中 ,研究药脂比对该体系性能的影响。方法 :选用相同用量的 4种表面活性剂 ,对SLN体系的平均粒径、Zeta电和包封率进行了测定 ,同时采用差示扫描量热法检测药物在载体中存在的晶型形态。结果 :当脂质质量不变 ,SLN系统的平均粒径随所载药物量增加而增加。在载药量为 5 0mg ,脂质质量为 1g时 ,包封率最高。同时 ,Zeta电位与胶体系统中游离药物量相关。DSC分析发现所有载药SLN试样均未出现米非司酮约 190℃熔点附近的吸热峰。结论 :载体所载模型药会影响系统的平均粒径和Zeta电位 ,即使在 2 5 0mg/ 1g(脂质 )的高载药量下 ,原本结晶性药物也是以无定形或者分子状态分散在SLN载体系统中的 ,目前尚未见到在如此高载药量下载体物理性状的相关报道。模型药米非司酮可以影响纳米系统的性能 ,另一方面 ,所加入药物的性能也被纳米尺度载体系统改变了。
Objective: The abortion drug mifepristone loaded solid lipid nanoparticles (SLNs), the study of the ratio of lipid to the performance of the system. Methods: The average particle size, Zeta potential and entrapment efficiency of SLN system were determined by using the same amount of four surfactants. Meanwhile, the crystal form of the drug in the carrier was detected by differential scanning calorimetry. Results: The average particle size of the SLN system increased with the amount of drug loaded when the lipid mass remained unchanged. In the drug load of 50mg, lipid quality 1g, the highest encapsulation efficiency. At the same time, Zeta potential is related to the amount of free drug in the colloidal system. DSC analysis showed that none of the loaded SLN samples showed an endothermic peak near the melting point of about 190 ° C for mifepristone. Conclusion: The model drug contained in the carrier affects the mean particle size and Zeta potential of the system. Even at a high drug loading of 250 mg / 1 g (lipid), the original crystalline drug is dispersed in the amorphous or molecular state in the SLN In the carrier system, no relevant reports on the physical properties of the carrier under such high drug loading have been found so far. The model drug mifepristone can affect the performance of the nanosystem, and on the other hand, the properties of the added drug are also altered by the nanoscale carrier system.